The serotonin transporter availability in untreated early-onset and late-onset patients with obsessive-compulsive disorder

International Journal of Neuropsychopharmacology

Volumn 14, Issue 5, 2011, Pages 606-617

  Hesse, Swen ^a   Stengler, Katarina ^a   Regenthal, Ralf ^a   Patt, Marianne ^a   Becker, Georg Alexander ^a   Franke, Annegret ^b   Knüpfer, Heike ^a   Meyer, Philipp M ^a   Luthardt, Julia ^a   Jahn, Ina ^a   Lobsien, Donald ^a   Heinke, Wolfgang ^a   Brust, Peter ^c   Hegerl, Ulrich ^a   Sabri, Osama ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b Clinical Trial Centre Leipzig   (Germany)

^c INSTITUTE OF ION BEAM PHYSICS AND MATERIALS RESEARCH   (Germany)

Author keywords

Obsessive compulsive disorder; positron emission tomography; serotonin transporter

Indexed keywords

CARBON 11; SEROTONIN TRANSPORTER; TRACER;

ADULT; ALLELE; AMYGDALOID NUCLEUS; ANTERIOR CINGULATE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DEPRESSION; DNA POLYMORPHISM; FEMALE; GENDER; HUMAN; HYPOTHALAMUS; LIMBIC SYSTEM; MALE; NUCLEUS ACCUMBENS; OBSESSIVE COMPULSIVE DISORDER; ONSET AGE; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PUTAMEN; STATISTICAL MODEL; THALAMUS;

ADULT; AGING; BRAIN; BRAIN MAPPING; CEREBRAL CORTEX; CORPUS STRIATUM; FEMALE; GENOTYPE; HUMANS; HYPOTHALAMUS; MALE; MIDDLE AGED; NUCLEUS ACCUMBENS; OBSESSIVE-COMPULSIVE DISORDER; POLYMORPHISM, GENETIC; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; THALAMUS; TIME FACTORS; YOUNG ADULT;

EID: 79956055430     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145710001604     Document Type: Article

References (55)

1. 2A receptor binding in the caudate nuclei. International Journal of Neuropsychopharmacoly 8, 391-401. (Pubitemid 41002493)
2. Babor TF, de la Fuente JR, Saunders J, Grant M (1986). AUDIT - The Alcohol Use Disorders Identification Test: Guidelines for Use in Primary Health Care. WHO/MNH/DAT 89.4. Geneva: World Health Organization.
3. Baumgarten HG, Grozdanovic Z (1998). Role of serotonin in obsessive-compulsive disorder. British Journal of Psychiatry 35 (Suppl.), 13-20. (Pubitemid 28368346)
4. Beck AT, Ward CH, Mendelson J, Mock J, et al. (1961). An inventory for measuring depression. Archives of General Psychiatry 4, 564-571.
5. Berman AH, Bergman H, Palmstierna T, Schlyter F (2005). Evaluation of the drug use disorders identification test (DUDIT) in criminal justice and detoxification settings and in a swedish population sample. European Addiction Research 11, 22-31. (Pubitemid 40082207)
6. Breiter HC, Rauch SL (1996). Functional MRI and the study of OCD: from symptom provocation to cognitive-behavioral probes of cortico-striatal systems and the amygdala. Neuroimage 4, S127-S138. (Pubitemid 27024281)
7. Buchert R, Schulze O, Wilke F, Berding G, et al. (2006). Is correction for age necessary in SPECT or PET of the central serotonin transporter in young, healthy adults? Journal of Nuclear Medicine 47, 38-42. (Pubitemid 46768510)
8. Denys D, Van Nieuwerburgh F, Deforce D, Westenberg HG (2006). Association between serotonergic candidate genes and specific phenotypes of obsessive compulsive disorder. Journal of Affective Disorder 91, 39-44. (Pubitemid 43254636)
9. Eggers B, Hermann W, Barthel H, Sabri O, et al. (2003). The degree of depression in Hamilton rating scale is correlated with the density of presynaptic serotonin transporters in 23 patients with Wilson's disease. Journal of Neurology 250, 576-580. (Pubitemid 36613301)
10. Erritzoe D, Frokjaer VG, Haahr MT, Kalbitzer J, et al. (2010). Cerebral serotonin transporter binding is inversely related to body mass index. Neuroimage 46, 23-30.
11. Fontenelle LF, Mendlowicz MV, Marques C, Versiani M (2003). Early- and late-onset obsessive-compulsive disorder in adult patients: an exploratory clinical and therapeutic study. Journal of Psychiatry Research 37, 127-133. (Pubitemid 36808475)
12. Goodman WK, Price LH, Rasmussen SA, Mazure C, et al. (1986a). The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Archives of General Psychiatry 46, 1006-1011.
13. Goodman WK, Price LH, Rasmussen SA, Mazure C, et al. (1986b). The Yale-Brown Obsessive Compulsive Scale. II. Validity. Archives of General Psychiatry 46, 1012-1016.
14. Gu XH, Zong R, Kula NS, Baldessarini RJ, et al. (2001). Synthesis and biological evaluation of a series of novel N- or O-fluoroalkyl derivatives of tropane: potential positron emission tomography (PET) imaging agents for the dopamine transporter. Bioorganic & Medicinal Chemical Letters 11, 3049-3053. (Pubitemid 33063627)
15. Harrison BJ, Soriano-Mas C, Pujol J, Ortiz H, et al. (2009). Altered corticostriatal functional connectivity in obsessive-compulsive disorder. Archives of General Psychiatry 66, 1189-1200.
16. Hasler G, Kazuba D, Murphy DL (2006). Factor analysis of obsessive-compulsive disorder YBOCS-SC symptoms and association with 5-HTTLPR SERT polymorphism. American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics 141B, 403-408. (Pubitemid 43872894)
17. Hasselbalch SG, Hansen ES, Jakobsen TB, Pinborg LH, et al. (2007). Reduced midbrain-pons serotonin transporter binding in patients with obsessive-compulsive disorder. Acta Psychiatrica Scandinavia 115, 388-394. (Pubitemid 46570063)
18. Heils A, Teufel A, Petri S, Stöber G, et al. (1996). Allelic variation of human serotonin transporter gene expression. Journal of Neurochemistry 66, 2621-2624. (Pubitemid 26159101)
19. Hesse S, Barthel H, Murai T, Müller U, et al. (2003). Is correction for age necessary in neuroimaging studies of the central serotonin transporter? European Journal of Nuclear Medicine and Molecular Imaging 30, 427-430. (Pubitemid 36692870)
20. Hesse S, Müller U, Lincke T, Barthel H, et al. (2005). Serotonin and dopamine transporter imaging in patients with obsessive-compulsive disorder. Psychiatry Research: Neuroimaging 140, 63-72. (Pubitemid 41443497)
21. 11C]AFM. Journal of Cerebral Blood Flow and Metabolism 22, 1377-1398. (Pubitemid 35285095)
22. 11C]DASB positron emission tomography studies of the serotonin transporter in human brain. Journal of Cerebral Blood Flow and Metabolism 23, 1096-1112. (Pubitemid 37082435)
23. Innis RB, Cunningham VJ, Delforge J, Fujita M, et al. (2007). Consensus nomenclature for in vivo imaging of reversibly binding radioligands. Journal of Cerebral Blood Flow and Metabolism 27, 1533-1539. (Pubitemid 47301451)
24. Jovanovic H, Lundberg J, Karlsson P, Cerin A, et al. (2008). Sex differences in the serotonin 1A receptor and serotonin transporter binding in the human brain measured by PET. Neuroimage 39, 1408-1419.
25. 11C]DASB: test-retest reproducibility using a multilinear reference tissue parametric imaging method. Journal of Nuclear Medicine 47, 208-214. (Pubitemid 46780884)
26. 123I]b-CIT: pharmacological characterization of brain uptake in nonhuman primates. Synapse 13, 295-309. (Pubitemid 23104535)
27. Leckman JF, Goodman WK, Anderson GM, Riddle MA, et al. (1995). Cerebrospinal fluid biogenic amines in obsessive compulsive disorder, Tourette's syndrome, and healthy controls. Neuropsychopharmacology 12, 73-86.
28. Lin PY (2007). Meta-analysis of the association of serotonin transporter gene polymorphism with obsessive-compulsive disorder. Progress in Neuropsychopharmacology and Biological Psychiatry 31, 683-689.
29. Lochner C, Stein DJ (2003). Heterogeneity of obsessive-compulsive disorder: a literature review. Harvard Review of Psychiatry 11, 113-132. (Pubitemid 36765070)
30. Lomax CL, Oldfield VB, Salkovskis PM (2009). Clinical and treatment comparisons between adults with early- and late-onset obsessive-compulsive disorder. Behaviour Research and Therapy 47, 99-104.
31. 11C]DASB PET study. Neuroimage 49, 121-126.
32. Millet B, Kochman F, Gallarda T, Krebs MO, et al. (2004). Phenomenological and comorbid features associated in obsessive-compulsive disorder: influence of age of onset. Journal of Affective Disorder 79, 241-246. (Pubitemid 38340550)
33. Nestadt G, Samuels J, Riddle M, Bienvenu III OJ, et al. (2000). A family study of obsessive-compulsive disorder. Archives of General Psychiatry 57, 358-363. (Pubitemid 30202326)
34. Ogilvie AD, Battersby S, Bubb VJ, Fink G, et al. (1996). Polymorphism in serotonin transporter gene associated with susceptibility to major depression. Lancet 347, 731-733. (Pubitemid 26085649)
35. 1 receptor binding in the striatum of patients with obsessive-compulsive disorder. Journal of Affective Disorder 114, 321-326.
36. Parsey RV, Hastings RS, Oquendo MA, Hu X, et al. (2006). Effect of a triallelic functional polymorphism of the serotonin-transporter-linked promoter region on expression of serotonin transporter in the human brain. American Journal of Psychiatry 163, 48-51. (Pubitemid 43050102)
37. Pauls DL, Alsobrook II JP, Goodman W, Rasmussen S, et al. (1995). A family study of obsessive-compulsive disorder. American Journal of Psychiatry 152, 76-84.
38. 2 dopamine dysfunction in drug-naive obsessive-compulsive disorder. Neuroimage 42, 306-314.
39. Pogarell O, Hamann C, Pöpperl G, Juckel G, et al. (2003). Elevated brain serotonin transporter availability in patients with obsessive-compulsive disorder. Biological Psychiatry 54, 1406-1413. (Pubitemid 37522165)
40. Radua J, Mataix-Cols D (2009). Voxel-wise meta-analysis of grey matter changes in obsessive-compulsive disorder. British Journal of Psychiatry 195, 393-402.
41. 11C]DASB PET study. Journal of Neural Transmission 114, 1603-1609. (Pubitemid 350212008)
42. 11C]DASB is affected by serotonin transporter genotype. Journal of Neural Transmission 114, 635-639. (Pubitemid 46664049)
43. Rosario-Campos MC, Leckman JF, Mercadante MT, Shavitt RG, et al. (2001). Adults with early-onset obsessive-compulsive disorder. American Journal of Psychiatry 158, 1899-1903. (Pubitemid 33054785)
44. Rotge JY, Langbour N, Guehl D, Bioulac B, et al. (2010). Gray matter alterations in obsessive-compulsive disorder: an anatomic likelihood estimation meta-analysis. Neuropsychopharmacology 35, 686-691.
45. Saiz PA, Garcia-Portilla MP, Arango C, Morales B, et al. (2008). Association study between obsessive-compulsive disorder and serotonergic candidate genes. Progress in Neuropsychopharmacology and Biological Psychiatry 32, 765-770. (Pubitemid 351320543)
46. Saxena S, Brody AL, Schwartz JM, Baxter LR (1998). Neuroimaging and frontal-subcortical circuitry in obsessive-compulsive disorder. British Journal of Psychiatry 35 (Suppl.), 26-37. (Pubitemid 28368348)
47. 11C]McN 5652. Biological Psychiatry 54, 1414-1421. (Pubitemid 37522166)
48. Smeraldi E, Diaferia G, Erzegovesi S, Lucca A, et al. (1996). Tryptophan depletion in obsessive-compulsive patients. Biological Psychiatry 40, 398-402. (Pubitemid 26301071)
49. Soomro GM, Altman D, Rajagopal S, Oakley-Browne M (2008). Selective serotonin re-uptake inhibitors (SSRIs) vs. placebo for obsessive compulsive disorder (OCD). Cochrane Database Systematic Reviews. Issue 1. Art No. CD001765.
50. 123I]b-CIT SPECT measures of dopamine and serotonin transporter availability in healthy smokers and nonsmokers. Synapse 41, 275-284. (Pubitemid 32702249)
51. Stengler-Wenzke K, Müller U, Angermeyer MC, Sabri O, et al. (2004). Reduced serotonin transporter-availability in obsessive-compulsive disorder (OCD). European Archives of Psychiatry and Clinical Neuroscience 254, 252-255. (Pubitemid 39312840)
52. Tükel R, Ertekin E, Batmaz S, et al. (2005). Influence of age of onset on clinical features in obsessive-compulsive disorder. Depression and Anxiety 21, 112-117.
53. 123I]b-CIT SPECT. American Journal of Psychiatry 161, 2201-2206. (Pubitemid 39587284)
54. 11C-labeled 2-(phenylthio)araalkylamines. Journal of Medicinal Chemistry 43, 3103-3110. (Pubitemid 30626767)
55. 123I]-b-CIT SPECT imaging shows reduced thalamus-hypothalamus serotonin transporter availability in 24 drug-free obsessive-compulsive checkers. Neuropsychopharmacology 32, 1661-1668. (Pubitemid 47076373)